Control of oral anticoagulant treatment by chromogenic prothrombin assay.
作者信息
O'Donnell J R, Walker I D, Davidson J F
出版信息
J Clin Pathol. 1987 May;40(5):500-4. doi: 10.1136/jcp.40.5.500.
Abstract
Doses of oral anticoagulants in 50 patients on long term treatment were easily and satisfactorily monitored over six months by an automated chromogenic assay of prothrombin (CPA). It is suggested that chromogenic assay of one or more of the vitamin K dependent coagulation factors would provide a readily standardised alternative to those conventional tests which depend on human brain derived reagents, now regarded as a biohazard.
摘要
相似文献
1
Control of oral anticoagulant treatment by chromogenic prothrombin assay.
J Clin Pathol. 1987 May;40(5):500-4. doi: 10.1136/jcp.40.5.500.
2
Oral anticoagulant control with a chromogenic substrate: calibration, precision and cost.
Clin Lab Haematol. 1982;4(1):27-39. doi: 10.1111/j.1365-2257.1982.tb00056.x.
3
A chromogenic assay of prothrombin compared with coagulation tests during anticoagulant therapy and liver disease.
Ric Clin Lab. 1981 Jul-Sep;11(3):215-22. doi: 10.1007/BF02890527.
4
5
Control of anticoagulant therapy with a chromogenic substrate.
Haemostasis. 1979;8(1):1-7. doi: 10.1159/000214285.
6
Plasma levels of factors II, VII and X and their relationship to the international normalized ratio during chronic warfarin therapy.
Blood Coagul Fibrinolysis. 1997 Jan;8(1):48-53. doi: 10.1097/00001721-199701000-00008.
7
Maintenance control of oral anticoagulant therapy by an automated chromogenic substrate assay of factor X.
Clin Lab Haematol. 1982;4(2):179-86.
8
Native prothrombin as an alternative to prothrombin time determination for monitoring oral anticoagulant therapy.
Clin Chem Lab Med. 2009;47(2):242-3. doi: 10.1515/CCLM.2009.046.
9
Oral anticoagulant prophylaxis and epidural catheter removal.
Reg Anesth. 1996 Nov-Dec;21(6):517-24.
10
Recurrent venous thrombosis despite 'optimal anticoagulation therapy' for antiphospholipid syndrome--could new oral anticoagulants solve the problem?
Acta Clin Croat. 2010 Dec;49(4):469-77.
本文引用的文献
1
Turnover of prothrombin, factor VII and factor IX in a patient with hemophilia A.
Scand J Clin Lab Invest. 1961;13:668-72. doi: 10.3109/00365516109137342.
2
Maintenance control of oral anticoagulant therapy by a chromogenic substrate assay for factor X.
J Clin Pathol. 1980 May;33(5):445-8. doi: 10.1136/jcp.33.5.445.
3
Use of chromogenic peptide substrates in the determination of clotting factors II, VII, IX and X in normal plasma and in plasma of patients treated with oral anticoagulants.
Haemostasis. 1982;12(3):241-55. doi: 10.1159/000214679.
4
Newer synthetic peptide substrates in coagulation testing: some practical considerations for automated methods.
Semin Thromb Hemost. 1983 Oct;9(4):250-62.
5
Evaluation of an automated prothrombin assay using a chromogenic substrate.
Haemostasis. 1984;14(4):307-11. doi: 10.1159/000215080.
6
Standardisation of oral anticoagulant treatment.
Br Med J (Clin Res Ed). 1983 Oct 8;287(6398):1000-1. doi: 10.1136/bmj.287.6398.1000.
7
Determination of plasma prothrombin with a reaction rate analyzer using a synthetic substrate.
Thromb Res. 1974 Jun;4(6):719-29. doi: 10.1016/0049-3848(74)90016-4.
8
Questions and answers on prothrombin time standardisation in oral anticoagulant control.
Thromb Haemost. 1985 Aug 30;54(2):515-7.
9
Therapeutic ranges in anticoagulant administration.
Br Med J (Clin Res Ed). 1985 Jun 8;290(6483):1683-6. doi: 10.1136/bmj.290.6483.1683.
10
Creutzfeldt-Jakob disease pathogen in growth hormone preparations is eliminatable.
Lancet. 1985 Dec 7;2(8467):1299-300. doi: 10.1016/s0140-6736(85)91576-4.
Zotero 插件